Arvin

Arvinas is a clinical-stage biotechnology company pioneering the development of a new class of drugs based on Proteolysis-Targeting Chimeras (PROTACs). The company's proprietary platform leverages the body's natural protein disposal system to selectively degrade disease-causing proteins, offering a potential advantage over traditional inhibitors. Arvinas' lead programs target the estrogen receptor for breast cancer and the androgen receptor for prostate cancer. By targeting "undruggable" proteins, the company aims to provide transformative treatments for patients with cancer, neurodegenerative disorders, and other serious diseases. Arvinas has established significant strategic collaborations with major pharmaceutical companies like Pfizer and Bayer to advance its pipeline.